Methods and compositions for treating coronavirus infections
AssigneeMorehouse School of Medicine
InventorsMichael POWELL, Erick Vidjin' Agnih Gbodossou
Life of this patent
Estimating the term…
Abstract
The present application relates to a compositions and methods comprising or expressing a HEVAR or MOMO30 protein derived from Momordica balsamina. The HEVAR or MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for treating or preventing viral infections, particularly those caused by coronaviruses, such as SARS-CoV-2.
Claims19
A method for treating or preventing a Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) infection, comprising orally administering to a subject in need thereof a composition comprising:
- an effective amount hevamine related (HEVAR) protein which comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:
- 15;
- and at least one pharmaceutically acceptable carrier.
A method for reducing or preventing the severity of the cytokine storm in a SARS-CoV-2 infected patient comprising:
- administering an effective amount of a pharmaceutical composition a pharmaceutical composition comprising an effective amount of a hevamine A-related plant protein which comprises an amino acid sequence that has at least 90% identical to SEQ ID NO:
- 15;
- and at least one pharmaceutically acceptable carrier, wherein the method results in at least a 20% reduction in cytokine levels for one or more of IL-6, IL-1β, IL-2, IL-10, IFN-γ, TNF-α, GM-CSF, or VEGF.
A pharmaceutical composition comprising:
- a substantially pure HEVAR protein which comprises an amino acid sequence at least 95% or 99% identical to SEQ ID NO:
- 15;
- and
- at least one pharmaceutically acceptable carrier.
A method for treating or preventing a SARS-CoV-2 infection, comprising administering to a subject in need thereof a pharmaceutical composition comprising:
- an effective amount of an expression vector operatively linked to a nucleic acid having a nucleotide sequence that is at least 95% identity to SEQ ID NO:
- 12 or SEQ ID NO:
- 13;
- and
- at least one pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.